VNL1.F CHINA HEALTH GRP HD-10

Healthcare Biotechnology Frankfurt Exchange
0.0011 EUR
Close of Nov 12, 2026
0.0005 0.0100
Market cap
EUR 1.11M
P/E
-
P/B
0.06x
ROE
-27.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is VNL1.F undervalued?

Graham number

The Graham number of CHINA HEALTH GRP HD-10 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CHINA HEALTH GRP HD-10 fundamental analysis

No fundamental analysis for CHINA HEALTH GRP HD-10 yet.

CHINA HEALTH GRP HD-10 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CHINA HEALTH GRP HD-10

China Health Group Inc., together with its subsidiaries, researches and develops bio, natural, and synthetic drugs in the People's Republic of China. It engages in the pharmacodynamics and clinical research of drugs; provision of post market and contracted pharmaceutical development services; and technological transfer and services for the research and development of drugs. The company was formerly known as Venturepharm Laboratories Limited and changed its name to China Heal…

Full company profile